Evidence map›Paper›PMID 29720710›Full record

ArticleScientific reports2018

A novel role for ATR/Rad3 in G1 phase.

Cathrine A Bøe, Tine W Håland, Erik Boye, Randi G Syljuåsen, Beáta Grallert

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. The POLD1Scientific reports · 2020
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Cathrine A BøeDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Tine W HålandDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Erik BoyeDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Randi G SyljuåsenDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Beáta GrallertDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. beata.grallert@rr-research.no.
Oslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Checkpoint kinases are important in cellular surveillance pathways that help cells to cope with DNA damage and protect their genomes. In cycling cells, DNA replication is one of the most sensitive processes and therefore all organisms carefully regulate replication initiation and progression. The checkpoint kinase ATR plays important roles both in response to DNA damage and replication stress, and ATR inhibitors are currently in clinical trials for cancer treatment. Therefore, it is important to understand the roles of ATR in detail. Here we show that the fission yeast homologue Rad3 and the human ATR regulate events also in G1 phase in an unperturbed cell cycle. Rad3Δ mutants or human cells exposed to ATR inhibitor in G1 enter S phase prematurely, which results in increased DNA damage. Furthermore, ATR inhibition in a single G1 reduces clonogenic survival, demonstrating that long-term effects of ATR inhibition during G1 are deleterious for the cell. Interestingly, ATR inhibition through G1 and S phase reduces survival in an additive manner, strongly arguing that different functions of ATR are targeted in the different cell-cycle phases. We propose that potential effects of ATR inhibitors in G1 should be considered when designing future treatment protocols with such inhibitors.

Indexed as

G1 PhaseAtaxia Telangiectasia Mutated ProteinsCell LineCell Line, TumorCell SurvivalCheckpoint Kinase 2HumansProtein Kinase InhibitorsSchizosaccharomycesSchizosaccharomyces pombe ProteinsS PhaseAtaxia Telangiectasia Mutated ProteinsATR protein, humanCheckpoint Kinase 2Protein Kinase Inhibitorsrad3 protein, S pombeSchizosaccharomyces pombe Proteins

Identifiers

PMID29720710
PMCPMC5931961
OpenAlexW2806323548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.